Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6823274 | 0.93 | PLK1 (0.37) | KDM4EALDH1A1KMT2A | |
| SCHEMBL7835694 | 0.82 | ESR1 (0.46) | KDM4ENPC1PKMRAB9AMAPT | |
| SCHEMBL4757844 | 0.73 | ALDH1A1 (0.41) | KDM4ENPC1PKMRAB9AALDH1A1 | |
| SCHEMBL6311776 | 0.71 | CYP1A1 (0.47) | KDM4ENPC1RAB9AHTTMAPT | |
| SCHEMBL1019222 | 0.60 | AR (0.49) | ARALDH1A1TSHR | |
| SCHEMBL12892651 | 0.59 | ALDH1A1 (0.36) | KDM4ERAB9AMAPTALDH1A1TSHR | |
| SCHEMBL19672678 | 0.58 | LMNA (0.35) | HTTMAPTARALDH1A1TSHR | |
| SCHEMBL5319294 | 0.58 | HPGD (0.61) | NPC1RAB9AHTTMAPTTDP1 | |
| SCHEMBL1021140 | 0.58 | HTT (0.59) | HTTMAPTALDH1A1TSHRLMNA | |
| SCHEMBL3187325 | 0.58 | MAPT (0.36) | KDM4ENPC1PKMRAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927309-B2 | Sulfur compounds and intermolecular compounds containing the same as the component compounds | NIPPON SODA CO., LTD. (JP) | 2005-08-09 | — | — | US | disclosed |
| US-20040176643-A1 | Novel sulfur compounds and intermolecular compounds containing the same as the component compounds | NIPPON SODA CO., LTD. (JP) | 2004-09-09 | — | — | US | disclosed |
| US-6740782-B2 | SUCH AS CLATHRATE 1,1,2,2-TETRAKIS(4-CHLOROSULFONYL-PHENYL)ETHYLENE; FOR IMPROVED PERFORMANCE DURING SEPARATION OF SUBSTANCES, CHEMICAL STABILIZATION, NON-VOLATILIZATION, SUSTAINED RELEASE, AND PULVERIZATION | NIPPON SODA CO., LTD. (JP) | 2004-05-25 | — | — | US | disclosed |
| US-20030130358-A1 | Such as clathrate 1,1,2,2-tetrakis(4-chlorosulfonyl-phenyl)ethylene; for improved performance during separation of substances, chemical stabilization, non-volatilization, sustained release, and pulverization | NIPPON SODA CO., LTD. (JP) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176643-A1 | Novel sulfur compounds and intermolecular compounds containing the same as the component compounds | CBS, TST, ABCB7 | KDM4E 3952/4885NPC1 2334/4885PKM 2625/4885 |
| US-20030130358-A1 | Such as clathrate 1,1,2,2-tetrakis(4-chlorosulfonyl-phenyl)ethylene; for improved performance during separation of substances, chemical stabilization, non-volatilization, sustained release, and pulverization | CBS, CCT4, TST | KDM4E 1586/4885NPC1 1113/4885PKM 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.